Sign up Australia
Proactive Investors - Run By Investors For Investors

Nanobiotix to present at immuno-oncology gathering this month

The company currently has seven clinical trials underway
picture of xray machine
Nanobiotix wants to trial its nano-xray therapy in a combination

Nanobiotix SA (EPN:NANO) has been invited to give two presentations to the Society for Immunotherapy of Cancer (SITC) conference this month for its flagship NBTXR3 treatment.

A pioneering approach to cancer, nanoparticles are injected directly into solid tumours to amplify the effects of shrinking treatment.

It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

The company currently has seven clinical trials underway but is also exploring NBTXR3’s potential in immuno-oncology in combination therapies.

An investigational new drug application is being prepared for a combination trial in the US with checkpoint inhibitors, another of promising research in cancer treatment.

In January, meanwhile, first results from a phase I/II trial in liver cancer patients are expected and will be presented to the ASCO GI conference.



PhilW.jpg
Why Invest In Nanobiotix SA? Read More Here

Register here to be notified of future NANO Company articles
View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

picture of drug research
August 23 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use